Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bayer’s Xarelto Matched Warfarin in Japanese Safety Study

July 25 (Bloomberg) -- Bayer AG’s Xarelto blood-thinner didn’t raise the risk of bleeding for irregular-heartbeat patients in a Japanese study comparing the medicine with warfarin, the former standard of care, the Leverkusen, Germany-based company said today.

The results confirmed those of the global Rocket study, Bayer said. The German drug and chemicals maker said in April it requested Japanese approval for Xarelto for irregular-heartbeat patients.

To contact the reporter on this story: Naomi Kresge in Zurich at nkresge@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.